In this edition of AI Prognosis: Quirky medical data tripping up sepsis algorithms, AI scribes for patients, and some AI biotech news.

In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.

The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.

Plus a buried alcohol study gets published, and a Biosecure update.

Hospital execs say they're working to mitigate the impacts of the looming cuts.

Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide

Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.

A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.

Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.

Thousands of HHS staff who shape policy have had their employment status changed to a designation that makes it easier for them to be fired.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.

The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.

For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…

Assessing the health secretary's biggest challenges, and a look at new rules that inject politics into the NIH.

In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.

Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law

Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.

Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.

In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.

Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found